IXICO plc
(“IXICO”, the “Company” or the “Group”)
New release of the IXI™ platform and advanced biomarker partnerships
IXI™ enhances platform scale and clinical trial operational efficiency to support IXICO’s TechBio strategy in neurological diseases
New collaborations will add additional capabilities to the IXI™ product and service offering
19 November 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging, biomarker analytics and diagnostics, today announced the latest release of IXI™, the Company’s proprietary AI-powered platform that enables the management, processing and advanced analysis of brain imaging data to support clinical decision-making and accelerate the development of new treatments for neurological diseases.
In addition, IXICO has announced technology collaborations with Neuropacs Corp and ZRO Imaging to expand the capabilities of IXI™ in Parkinson’s disease and PET imaging respectively.
Latest IXI™ Release
The latest IXI™ release incorporates a significant programme of underlying technology development that advances Platform infrastructure, design and user-experience (UX) to deliver greater clinical trial operational efficiency and image quality control. Work has also been conducted to extend the scalability of IXI™ for external commercial use, wider adoption and integration. In doing so, IXICO is delivering on its roadmap to serve new commercial opportunities through technology licensing, integration and strategic partnerships.
IXI™ Collaborations
IXICO has agreed two new technology collaborations with Neuropacs Corp and ZRO Imaging as part of its strategy to transform IXI™ into a comprehensive, one-stop marketplace for advanced neurological imaging biomarkers. Complementing IXICO’s proprietary biomarker technology, Neuropacs Corp brings its De Novo authorised neuropacs™ FDA validated AIDP algorithm for Parkinson’s disease differentiation, while ZRO Imaging expands the Group’s PET imaging capabilities through advanced PET imaging methodologies and quantitative analysis tools for Alzheimer’s disease and other neurodegenerative disorders.
These collaborations enable IXICO to offer a broader range of cutting-edge third-party technologies through a single, integrated platform, simplifying customer access to advanced biomarker analysis tools and strengthening IXICO’s position as a technology partner to the neuroscience drug development industry.
Mark Austin, Chief Technology Officer of IXICO, commented: “This latest release represents another important step in the evolution of IXI™ and the delivery of our TechBio strategy. By making the platform more scalable and easier to integrate with external technologies, we are improving the efficiency of our core iCRO services while creating new opportunities to generate recurring revenues through technology licensing and partnerships. The recognition last week at the Citeline Biotech Awards 2026, winning Technology Innovation of the Year, provides powerful independent validation of the innovation and capabilities underpinning IXI™ and its potential to transform neurological imaging in clinical trials.
We are also delighted to collaborate with Neuropacs Corp and ZRO Imaging, whose technology expands the range of advanced imaging biomarkers we can offer customers.
Together, these developments bring us closer to our ambition of creating a one-stop platform and leading technology destination, enabling customers to access more capabilities through IXICO while expanding our addressable market and creating opportunities for growth.”
Ends
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
|
About IXI™
Designed by neuroscience and data science experts, the IXI™ Platform is a proprietary suit of technologies and AI tools tailor-made for neurological disease complexity. IXI™ uses machine learning and deep learning to reliably process data from global trials and build algorithms that precisely measure key imaging biomarkers associated with the identification, progression and treatment of Alzheimer’s, Parkinson’s, Huntington’s and other rare neurological diseases. It is the only technology platform of its kind specifically built for, and exclusively focussed on, neuroimaging processing and neurological biomarker analysis.
IXI™ is being used every day across the world. With over 30 cutting edge analytics algorithms the Platform integrates standardised high quality image data capture, image reading, advanced analysis and regulatorily compliant reporting of clinical data. IXI™ supports the biopharma industry to develop new medicines and diagnostic measures, informing decisions earlier in the drug development process via a single end to end platform.
About IXICO www.ixico.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.
About Neuropacs Corp www.neuropacs.com
Neuropacs Corp. builds AI software that uses brain imaging to study neurodegenerative diseases. Its platform runs on free-water diffusion MRI through a secure cloud workflow. It helps detect disease, measure neurodegeneration, support clinical diagnosis and improve how clinical trials are run. The company's lead product, neuropacs™ AIDP, received FDA De Novo classification as the first-ever Parkinsonian syndrome diagnostic aid. It helps clinicians tell Parkinson's disease apart from multiple system atrophy parkinsonian variant or progressive supranuclear palsy. Two more tools extend the platform to cognitive decline and dementia: neuropacs™ AIDD for differential diagnosis of dementia, including Alzheimer's disease and dementia with Lewy bodies, and neuropacs™ AIND for quantifying neurodegeneration. Its mission is to speed up the development of disease-modifying therapies by giving trial sponsors, researchers and clinicians better diagnostic insight and better ways to sort patients into groups. Important Safety Information: The neuropacs™ AIDP system is intended to provide supplemental information and is not a standalone diagnostic device. Results should be interpreted in conjunction with clinical evaluation and other diagnostic testing. This device does not rule out other potential causes of Parkinsonism symptoms or signs and is intended to be used after all other potential causes of Parkinsonism symptoms (such as dementia with Lewy bodies, vascular Parkinsonism, drug-induced Parkinsonism, and corticobasal degeneration/syndrome) have been ruled out by trained clinicians on the basis of clinical, neurological, and other laboratory tests. Patient management decisions should not be based solely on neuropacs™ AIDP output.
About ZRO Imaging www.zroimaging.com
ZRO Imaging is a specialist neuroimaging company focused on advanced PET imaging, quantitative image analysis, and biomarker development for neurodegenerative diseases. Combining scientific expertise with clinical trial imaging capabilities, ZRO supports pharmaceutical and biotechnology companies in the development, validation, and application of imaging biomarkers. Its expertise spans PET and MRI methodologies, advanced image analysis, and the development of quantitative imaging tools to support therapeutic development across Alzheimer’s disease and other neurodegenerative disorders.